Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments

Objective. To estimate the prevalence of chronic kidney disease (CKD) 3b – 5 stages and the newly diagnosed sustained reduction in glomerular filtration rate (GFR) <30 ml / min / 1.73 m2 in patients with atrial fibrillation (AF) in real clinical practice, as well as the features of their anticoagulant therapy.
Materials and Methods. Retrospectively, data of all discharge epicrisis from cardiological departments of five Moscow hospitals from June 1, 2016 to May 31, 2017 were analyzed. Patients over 18 years old with AF were enrolled. At the next stage, patients with CKD 3 b – 5 st and newly diagnosed sustained reduction in GFR <30 ml / min / 1.73 m2 (at least 2 measurements during hospitalization) were selected.
Results. Data of 9725 patients were analyzed, AF was diagnosed in 2983 (31 %) cases, of which a decreased GFR <45 ml / min / 1.73 m2 was detected in 27 % (n = 794) cases. Among them, 349 (44 %) were diagnosed with CKD 3b st, 123 (15 %) with CKD 4 st, 44 (6 %) with CKD 5 st, 278 (35 %) had a newly diagnosed sustained reduction in GFR. In 63 % of patients with AF and GFR <45 ml / min / 1.73 m2, anemia was diagnosed, 39 % of them had moderate and severe one. 711 (89 %) patients were prescribed anticoagulants, 53 % were assigned direct oral anticoagulants (DOACs). Patients with CKD 3 b st. more often rivaroxaban 15 mg (29 %) was prescribed, with CKD 4 and CKD 5 – warfarin (48 % and 25 %, respectively), in patients with newly diagnosed sustained reduction in GFR <30 ml / min / 1.73 m2 – apixaban 10 mg / day (16.2 %).
Conclusion. A quarter of patients with AF revealed a decreased GFR <45 ml / min / 1.73 m2, half of them were recommended DOACs. 42 % of patients with GFR <30 ml / min / 1.72 m2 were prescribed DOACs, 27 % – warfarin. Patients with CKD 5 st DOACs were not assigned; in half of cases, none of the anticoagulants was recommended. Most often, the dose of the prescribed anticoagulant was not counted according to GFR in patients with newly diagnosed sustained reduction in GFR <30 ml / min / 1.73 m2.

1. Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. Journal of Community Hospital Internal Medicine Perspectives. 2019;9(2):113–20. DOI: 10.1080/20009666.2019.1593781

2. Reinecke H, Nabauer M, Gerth A, Limbourg T, Treszl A, Engelbertz C et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney International. 2015;87(1):200–9. DOI: 10.1038/ki.2014.195

3. Gendlin G.E., Reznik E.V., Storojhakov G.I., Melekhov A.V., Fedorovskaya T.V. The relationship of atrial fibrillation and renal function in patients with chronic heart failure. Nephrology and Dialysis. 2010;12(4):254–61. In Russian

4. Melekhov A.V. Atrial fibrillation and chronic kidney disease: correction of treatment. Therapy. 2017;2(12):20–7. In Russian

5. Barysheva O.Yu., Kopyl V.E. Chronic kidney disease: prevalence, causes according to the register of the city polyclinic. CardioSomatics. 2017;8(1):85– 6. In Russian

6. Albrecht D, Turakhia M, Ries D, Marbury T, Smith W, Dillon D et al. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. Thrombosis and Haemostasis. 2017;117(11):2026–33. DOI: 10.1160/TH16-10-0815

7. Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. Clinical Journal of the American Society of Nephrology. 2018;13(7):1085–95. DOI: 10.2215/CJN.00340118

8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

9. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039

10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561

11. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal. 2012;33(22):2821–30. DOI: 10.1093/eurheartj/ehs274

12. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI: 10.1093/eurheartj/ehr342

13. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RELY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis. Circulation. 2014;129(9):961–70. DOI: 10.1161/CIRCULATIONAHA.113.003628

14. Weir MR, Kreutz R. Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants. Mayo Clinic Proceedings. 2018;93(10):1503–19. DOI: 10.1016/j.mayocp.2018.06.018

15. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

16. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330–93. DOI: 10.1093/eurheartj/ehy136

17. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. American Journal of Kidney Diseases. 2018;71(3):423– 35. DOI: 10.1053/j.ajkd.2017.09.026

18. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney International supplements. 2013;3(1):1–150. [ Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf ]

19. Ministry of Health of Russian Federation. Clinical recommendations: Atrial fibrillation and flutter in adults. (CP382). 2016. In Russian. Available at: http://webmed.irkutsk.ru/doc/pdf/fedaf.pdf

20. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/ NMH/NHD/MNM/11.1). Available at: https://www.who.int/vmnis/indicators/haemoglobin.pdf.2011.

21. Kiuchi MG. Atrial fibrillation and chronic kidney disease: A bad combination. Kidney Research and Clinical Practice. 2018;37(2):103–5. DOI: 10.23876/j.krcp.2018.37.2.103

22. Barrios V, Escobar C, Calderón A, Zamorano JL. Prevalence of renaldysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. Future Cardiology. 2014;10(2):215–20. DOI: 10.2217/fca.14.2

23. Mazalov K.V., Frolova I.A., Kamardina N.A., Mazalova M.E., Kozlova N.N., Seredneva L.R. Non-valve atrial fibrillation and chronic kidney disease, clinical and laboratory parallels. 2017. In Russian [Internet] 2017. Available at: https://racvs.ru/events/archive/xxiii_vserossiyskiy_sezd_serdechnososudistykh_khirurgov/neklapannaya_fibrillyatsiya_predserdiy_i_khronicheskaya_bolezn_pochek_klinikolaboratornye_paralleli_/

24. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2(1):1–141. [Available at: https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf ]

25. Ryu S-R, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH et al. The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Journal of Korean Medical Science. 2017;32(2):249. DOI: 10.3346/jkms.2017.32.2.249

26. Xu D, Murakoshi N, Sairenchi T, Irie F, Igarashi M, Nogami A et al. Anemia and Reduced Kidney Function as Risk Factors for New Onset of Atrial Fibrillation (from the Ibaraki Prefectural Health Study). The American Journal of Cardiology. 2015;115(3):328–33. DOI: 10.1016/j.amjcard.2014.10.041

27. Bonde AN, Lip G, Staerk L, Gundlund A, Torp-Pedersen C, Gislason G et al. Oral anticoagulation in atrial fibrillation and anemia: a report from danish nationwide registries. Journal of the American College of Cardiology. 2018;71(11):A508. DOI: 10.1016/S0735-1097(18)31049-0

28. Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. European Heart Journal. 2015;36(5):297–306. DOI: 10.1093/eurheartj/ehu139

29. Ramagopalan SV, Stamp E, Sammon CJ, Besford M, Carroll R, Mehmud F et al. Renal function and oral anticoagulant treatment of incident non-valvular atrial fibrillation: a retrospective study. Future Cardiology. 2019;15(4):301–9. DOI: 10.2217/fca-2019-0012

30. Feldberg J, Patel P, Farrell A, Sivarajahkumar S, Cameron K, Ma J et al. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology Dialysis Transplantation. 2019;34(2):265–77. DOI: 10.1093/ndt/gfy031

31. Coleman CI, Martinez BK, Turpie AGG, Sood N, Bunz TJ, Kreutz R. Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease. Blood. 2017;130(Supplement 1):2393–2393. DOI: 10.1182/blood.V130.Suppl_1.2393.2393

32. Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017;37(4):412–9. DOI: 10.1002/phar.1905

33. Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke A-K et al. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. The American Journal of Medicine. 2019;132(9):1078–83. DOI: 10.1016/j.amjmed.2019.04.013

34. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138(15):1519–29. DOI: 10.1161/CIRCULATIONAHA.118.035418